United States: FDA Promises Guidance On Lawful Off-Label Promotion

Earlier this month, the U.S. Food and Drug Administration (the "FDA") announced that by the end of the year, the agency would issue a draft guidance document addressing the contours of lawful and unlawful off-label promotion.1 The healthcare industry has heralded this announcement as a positive step in a regulatory environment that, many believe, provides unclear direction regarding the provision of truthful information to healthcare providers, leaving industry players vulnerable to FDA regulatory enforcement, criminal prosecution, and civil suits under the False Claims Act ("FCA").

While the FDA's announcement was welcomed by many after years of uncertainty and after recent events raised new questions about the constitutionality of the ban on off-label promotion, questions remain about the ultimate effect of the FDA's decision. First, will the agency provide clear statements regarding the scope of lawful and unlawful off-label promotion, or merely restate existing policy? Other agencies, including the Federal Trade Commission ("FTC") and the Securities and Exchange Commission ("SEC") have been criticized for issuing "new" guidance documents that simply restate the same ambiguous advice that prompted the industry to request their issuance.2 The FDA has not provided any indication of what its draft guidance will say, and in the absence of an accompanying revision to applicable regulations, it is difficult to predict whether the FDA's guidance will provide clear advice to the pharmaceutical and medical device industries.

Second, what effect will this guidance have on criminal prosecution and FCA actions based on off-label promotion? While modified guidance could redirect enforcement actions from the FDA itself, the laws that enable the Department of Justice ("DOJ") to pursue criminal and civil suits for selling a "misbranded" product or causing the submission of a "false claim" under the FCA may be unaffected by a guidance document from the FDA unless other laws and regulations are also amended.

This Alert provides an overview of the events prompting the FDA's announcement and addresses the questions left open by the FDA's decision.

I. Recent Events Leading to the FDA's Announcement

In July 2011 and September 2013, several companies submitted Citizen Petitions to the FDA requesting greater clarity for drug and device manufacturers to provide "truthful and non-misleading scientific information" regarding uses for drugs and devices beyond those that were approved by the FDA.3 The 2011 Petition requested clarity regarding several topics, including unsolicited requests for information from healthcare providers. The 2013 Petition built on the same areas addressed in the 2011 Petition and incorporated an additional discussion regarding the constitutionality of the FDA's effective ban on off-label promotion in light of the Second Circuit's decision in United States v. Caronia, 703 F.2d 149 (2d Cir. 2012), which held that the FDA's ban on truthful off-label promotion violated the First Amendment.4

The FDA responded, in part, to both Petitions in two Guidance documents issued in December 20115 and February 2014.6 Both Guidance documents provided some additional information about the appropriate distribution of scientific information regarding off-label uses, but left several questions unanswered. The FDA also notably reminded manufacturers that a manufacturer's "intended use" of a product may be established by circumstantial evidence,7 and that a drug "that is accompanied by written, printed, or graphic matter that suggests an unapproved use . . . would be considered misbranded.8

II. FDA's Response

Although the FDA has partially responded to the 2011 and 2013 Petitions, the FDA acknowledged in its announcement that several issues raised in the petitions remain unresolved, including unsolicited requests from healthcare providers about off-label use, manufacturers' ability to distribute scientific and medical information on unapproved new uses, manufacturer discussions regarding scientific information "more generally," and the dissemination of healthcare economic information.9

The letter also contains references to some of the same ambiguous guidance contained in prior Agency announcements, indicating that the FDA's upcoming guidance may not answer many of the questions that plague the current regulatory environment. The letter notes that the Federal Food, Drug, and Cosmetic Act (the "FDCA") operates to ensure the use of medical products is based on "sound evidence"10 and that distributing scientific information regarding off-label use may qualify in "appropriate circumstances."11 These ambiguous terms may leave the industry in the same constitutional and regulatory quandary that has effectively foreclosed the distribution of truthful scientific information regarding off-label use.

III. The Potential Effect on Criminal and Civil Actions Based on Off-Label Promotion

While clearer Guidance from the FDA regarding off-label promotion will be welcomed by the industry, the precise effects of this Guidance on criminal and civil suits are unknown. The DOJ has repeatedly taken the position that off-label promotion reflects a manufacturer's intent to sell a "misbranded" product, a position that is supported by FDA Guidance documents.12 Until Congress revises the FDCA, drug and device manufacturers may find the FDA's Guidance fails to provide sufficient assurance that changes to marketing practices will not result in criminal exposure. This is especially true in light of the extraordinarily severe consequences for manufacturers convicted of selling a "misbranded" product, which can include debarment and exclusion from government healthcare programs.13

Second, even if the FDA's upcoming Guidance provides the industry with a clearer regulatory framework to provide truthful information regarding off-label uses, it is open to question whether promotion expressly permitted by the FDA may still subject a manufacturer to liability under the FCA. As we previously discussed in our Alert regarding the Caronia decision, the law permits physicians to use their medical judgment to prescribe drugs for any indication regardless of FDA approval. Medicare and Medicaid, however, may only reimburse a prescription for a "medically accepted indication"—defined as a use approved by the FDA or supported by one of three compendia—and some courts have held that a request for reimbursement for such a prescription constitutes a "false claim" for payment under the FCA.14 The DOJ and the whistleblowers awarded standing in FCA cases—known as qui tam relators—have used this premise many times to allege that off-label promotion "causes" a false claim for payment by encouraging off-label prescriptions, a subset of which may be submitted to Medicare or Medicaid under 31 U.S.C. § 3729(a)(1)(A).

In FCA cases based on off-label promotion, an underlying premise has been that the manufacturer engaged in unlawful activity, which caused the "false claim" for government payment (a non-reimbursable, off-label prescription). Indeed, government actions for off-label promotion typically combine both criminal suits—for selling a "misbranded" product—and civil suits—for causing the submission of a "false claim"—based on the same underlying activity.15 If the FDA provides clear guidance delineating the scenarios in which manufacturers may provide truthful information regarding off-label use of a drug or device, it is open to question whether activities expressly permitted by the FDA could still give rise to FCA liability.

IV. Conclusion

The FDA's promise to release more guidance for manufacturers that want to distribute truthful information regarding their products was welcome news in a regulatory environment that has been characterized by uncertainty. Patterson Belknap will continue to monitor developments in this area, and will provide further information when the FDA releases its guidance later this year.

Footnotes

1 See Letter from L. Kux, Assistant Commissioner for Policy at the Food & Drug Administration to A. Bennett, J. McPhee et al., dated Jun. 6, 2014.

2 See Marlisse Silver Sweeney, Corporate Counsel, "Define 'Reasonable' When it Comes to Data Security" (June 11, 2014) (discussing the FTC's guidance that dictates that companies should employ a "reasonableness" standard for data security and the challenges faced by companies attempting to apply this standard); Criminal Division of the Department of Justice and the Enforcement Division of the U.S. Securities and Exchange Commission, "A Resource Guide to the U.S. Foreign Corrupt Practices Act" (Nov. 14, 2012); Law360, "How Companies Should Use New FCPA Guidance" (Nov. 15, 2012) (noting that the FCPA Resource Guide "does not announce new policies or provide guidance that could not otherwise be gleaned from existing cases, settlements and opinion letters").

3 See Citizen Petition from A. Bennett, P. Kalb et al. to the Division of Dockets Management of the Food and Drug Administration, dated July 5, 2011 (the "2011 Petition"); Citizen Petition from A. Bennett, C. Klasmeier et al. to the Division of Dockets Management of the Food and Drug Administration, dated Sept. 3, 2013 (the "2013 Petition").

4 2013 Petition at 2. We issued an alert detailing that decision and addressing its potential effect on False Claims Act Defendants. Patterson Belknap Alert, "Second Circuit Declares Off-Label Promotion Ban Unconstitutional: Implications for False Claims Act Defendants" (January 2013), available at http://www.pbwt.com/alert-second-circuit-declares-off-label-promotional-ban-unconstitutional/ .

5 See FDA Draft Guidance, "Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices" (Dec. 2011), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf (the "December 2011 Draft Guidance"). The FDA also published a request for information and comments on "scientific exchange" to assist the Agency's evaluation of its policies on communications regarding off-label use. See 76 Fed. Reg. 81,508 (Dec. 28, 2011).

6 See FDA Draft Guidance, "Distributing Scientific and Medical Publications on Unapproved New Uses – Recommended Practices" (Feb. 2014), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM387652. pdf (the "February 2014 Revised Draft Guidance").

7 Id. at 3–4.

8 Id. at 4.

9 Letter from L. Kux, Assistant Commissioner for Policy at the Food & Drug Administration to A. Bennett, J. McPhee et al., dated Jun. 6, 2014, at 9.

10 Id. at 7.

11 Id.

12 February 2014 Revised Draft Guidance at 4 ("[A]n approved new drug that is accompanied by written, printed, or graphic matter that suggests an unapproved new drug with respect to that use . . . would be considered misbranded, because the drug does not meet the regulatory exemptions from the requirement that its labeling bear 'adequate instructions for use.'").

13 See 21 U.S.C. § 335a.

14 Patterson Belknap Alert, "Second Circuit Declares Off-Label Promotion Ban Unconstitutional: Implications for False Claims Act Defendants" (January 2013), available at http://www.pbwt.com/alert-second-circuit-declares-off-label-promotional-ban-unconstitutional/ .

15 See, e.g. Department of Justice Press Release, "Par Pharmaceuticals Pleads Guilty and Agrees to Pay $45 Million to Resolve Civil and Criminal Allegations Related to Off-Label Marketing" (Mar. 5, 2013), available at http://www.justice.gov/opa/pr/2013/March/13-civ-270.html (discussing combined settlement for criminal suit based on selling a "misbranded" product and a civil suit for causing submissions of "false claims" for off-label prescriptions in violation of the FCA).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.